Leman Biotech received the prestigious "CGT Industry Star" Technology Breakthrough of the Year award at the CGT Asia 2023 3rd Asia Cell and Gene Therapy Innovation Summit held in Shanghai on April 3-4, 2023. Dr. Dudu Tong, R&D Director of Leman Biotech, received the award on behalf of the company.
Leman Biotech's groundbreaking "AI-enabled metabolism-enhanced immunotherapy," based on its metabolic reprogramming technology Meta 10, was recognized for its significant contribution to the field of T-cell immunotherapies by addressing T-cell exhaustion. The therapy effectively enhances the response and cure rates of existing immunotherapies, such as CAR-T, TCR-T, TILs, and PD-1 antibodies. By collaborating with industry peers, Leman Biotech aims to expand the application of Meta 10 to a wide range of immunotherapies, targets, and indications, and to accelerate the development of next-generation immunotherapies and benefit a larger number of patients with various types of tumors.
The "CGT Industry Star" Technology Breakthrough of the Year award, organized by Taas Labs, acknowledges Leman Biotech's innovative approach and significant contributions to the field of cell and gene therapy.
